Neuroimmune Consortium: Biomarker Tool Development


A well-recognized hallmark of Alzheimer’s disease (AD) is the activation of the brain’s immune system, sometimes called neuroinflammation. Despite having detailed information about neuroinflammation in AD from pathology samples after death, we have very limited tools for understanding neuroinflammation at the early stages of AD in living people. To address this need, we are developing imaging agents for use in positron emission tomography (PET) that will help characterize neuroinflammation.

Funding to Date



Studies of Innate Immune Pathology, Translational


Jacob Hooker, Ph.D.